February 03, 2020 07:29 AM Eastern Standard Time
SOMERSET, N.J. & GOSSELIES, Belgium–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space,” said John Chiminski, Catalent’s Chair & Chief Executive Officer. “Both autologous and allogeneic cell therapies provide important new treatment options, with a rising number expected to gain regulatory approval over the coming years. Catalent is well-positioned to combine MaSTherCell’s expert teams and capabilities with our extensive resources and experience in scaling new platforms, and to help MaSTherCell build-out its development and commercial manufacturing capabilities.”
Orgenesis Inc is headquartered in Germantown, Maryland which is in the heart of the Biohealth Capital Region. In the past year, Catalent completed two other acquisitions from Maryland-based companies, including Paragon Gene Therapy for $1.2B and a portion of Novavax, Inc’s business which expanded their operations into Montgomery County with a cGMP manufacturing facility.